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Abstract
Introduction: Early diagnosis of sepsis is vital to the clinical course and outcome of septic patients. Recently,
soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) appears to be a potential marker of infection.
The objective of this systematic review and meta-analysis was to evaluate the accuracy of plasma sTREM-1 for
sepsis diagnosis in systemic inflammatory patients.
Methods: A systematic literature search of PubMed, Embase and Cochrane Central Register of Controlled Trials was
performed using specific search terms (up to 15 October 2012). Studies were included if they assessed the
accuracy of plasma sTREM-1 for sepsis diagnosis in adult patients with systemic inflammatory response syndrome
(SIRS) and provided sufficient information to construct a 2 X 2 contingency table.
Results: Eleven studies with a total of 1,795 patients were included. The pooled sensitivity and specificity was 79%
(95% confidence interval (CI), 65 to 89) and 80% (95% CI, 69 to 88), respectively. The positive likelihood ratio,
negative likelihood ratio and diagnostic odds ratio were 4.0 (95% CI, 2.4 to 6.9), 0.26 (95% CI, 0.14 to 0.48), and 16
(95% CI, 5 to 46), respectively. The area under the curve of the summary receiver operator characteristic was 0.87
(95% CI, 0.84 to 0.89). Meta-regression analysis suggested that patient sample size and assay method were the
main sources of heterogeneity. Publication bias was suggested by an asymmetrical funnel plot (P = 0.02).
Conclusions: The present meta-analysis showed that plasma sTREM-1 had a moderate diagnostic performance in
differentiating sepsis from SIRS. Accordingly, plasma sTREM-1 as a single marker was not sufficient for sepsis
diagnosis in systemic inflammatory patients.
Introduction
Sepsis is a life-threatening complication of infection and
the most common cause of death in intensive care units
(ICU) [1]. Delay in diagnosis and treatment often results
in rapid progression to circulatory collapse, multiple
organ failure and eventual death [2]. Therefore, accurate
and timely diagnosis of sepsis will limit morbidity,
reduce costs and improve patients’ outcome [3-5].
Diagnosis of sepsis is based on systemic inflammatory
response syndrome (SIRS) in the presence of a known
infection. SIRS is very common in critically ill patients,
being found in various conditions, including trauma,
surgery and pancreatitis [6,7]. Microbiological culture as
a gold standard is used to distinguish sepsis from non-
infectious conditions. However, this method lacks sensi-
tivity, and there is often a substantial time delay. Thus,
there is an urgent need for a fast, simple and accurate
method to enhance sepsis diagnosis.
The triggering receptor expressed on myeloid cells-1
(TREM-1) was a recently discovered member of the
immunoglobulin superfamily, expression of which on
phagocytes was up-regulated by exposure to bacteria
and fungi [8]. TREM-1 mediated the acute inflammatory
response to microbial products. A soluble form of
TREM-1 (sTREM-1) is released from the activated pha-
gocytes and can be found in body fluids, such as plasma
[9], pleural fluid [10], bronchoalveolar lavage fluid [11],
urine [12] and cerebrospinal fluid [13]. Thus, sTREM-1
may act as a potential biomarker of bacterial infection
[14,15]. Recently, several studies have been performed to
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investigate the role of plasma sTREM-1 in differentiat-
ing sepsis from non-infectious SIRS in different settings
[9,16-25]. Due to the limited patient sample size
recruited in the individual studies, we aimed to conduct
a systematic review and meta-analysis to assess the role
of plasma sTREM-1 for sepsis diagnosis in adult patients
with SIRS.
Materials and methods
This systematic review and meta-analysis was performed
according to the guidelines of Meta-analysis of Observa-
tional Studies in Epidemiology [26].
Search strategy
PubMed, Embase and Cochrane Controlled Clinical
Trials Register Database (up to 20 June 2012) were
searched by using Exploded Medical Subject Headings
and the appropriate corresponding keywords, ‘’triggering
receptor expressed on myeloid cells-1’’, ‘’soluble trigger-
ing receptor expressed on myeloid cells-1’’, ‘’TREM-1’’,
‘’sTREM-1’’. We updated the literature search of the
above electronic databases on 15 October 2012 to find
as many eligible studies as possible. No language restric-
tion was used. Further searches were performed by
checking the reference lists from primary and review
articles, and manually reviewing abstract booklets and
conference proceedings. The authors were contacted for
study details if needed.
Eligibility criteria and study selection
Studies were included if they assessed the accuracy of
plasma sTREM-1 for sepsis diagnosis in adult patients
with SIRS and provided sufficient information to construct
a 2 X 2 contingency table. Two reviewers independently
judged study eligibility when screening the citations. Dis-
agreements were resolved by consensus. Agreement
regarding study inclusion was assessed using the Cohen Κ
statistic [27].
Data extraction
Two reviewers independently abstracted data in each
study to obtain information on the year of publication,
country of origin, clinical setting, sample size, patients’
demographics, sTREM-1 test methods, diagnostic cut-
off points, sensitivity, specificity and methodological
quality. Each reviewer extracted the data to construct a
2 X 2 contingency table.
Definitions
Sepsis was defined according to the criteria proposed by
the American College of Chest Physicians/Society of
Critical Care Medicine as the presence of an infection
complicated by SIRS [28]. Patients included in the septic
group had either microbiologically (culture-proven) or
clinically diagnosed sepsis, whereas the other patients
were included in the non-infectious SIRS group.
Quality assessment
The methodological quality of each study was graded
independently by two reviewers with the Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS) tool, a
validated tool for the quality assessment of diagnostic
accuracy studies [29]. Furthermore, studies were
grouped according to Sackett and Haynes’ [30] classifi-
cation of diagnostic studies. In this classification, phase
1 studies are those that compare the difference in test
results between patients with the target disorder and
healthy individuals. Phase 2 studies are those that exam-
ine how the index test discriminates between patients
with and without the target disorder. Phase 3 studies are
those that assess the test’s real-life performance in
patients suspected of having the disorder.
Statistical analysis
The diagnostic meta-analysis was performed using a
bivariate meta-analysis model [31] to calculate the
pooled sensitivity, specificity, positive/negative likelihood
ratios, and diagnostic odds ratio (DOR). The summary
receiver operator characteristic (SROC) curve that
plotted sensitivity versus specificity was constructed to
plot the individual and summary points of sensitivity
and specificity [32]. Furthermore, around the pooled
estimate, we also plotted a 95% confidence region and a
95% prediction region to illustrate the precision with
which the pooled value was estimated (confidence
ellipse of a mean) and to show the amount of between
study variation (prediction ellipse; the likely range of
values for a new study). The presence of statistical
between-study heterogeneity was assessed by the I2 test
[33]. Values of 25, 50 and 75% for the I2 test were
regarded as indicative of low, moderate and high statisti-
cal heterogeneity, respectively. Meta-regression analysis
using a bivariate model was performed in order to find
the effect of potentially confounding covariates. Each
covariate had a fixed effect when added to the bivariate
model and associated with logit(sensitivity) and/or logit
(specificity) [34]. Publication bias through small study
effects was assessed with a regression test on the diag-
nostic odds ratio [35,36]. A P-value <0.05 was consid-
ered as indicative of statistical significance. Stata
intercooled version 10.1 (StataCorp, College Station, TX,
USA) was used for all statistical analyses.
Results
Study characteristics
The initial search yielded 664 citations, of which 15
publications dealing with sTREM-1 for sepsis diagnosis
were considered as potentially suitable for inclusion.
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After full-text review, seven studies were excluded: three
studies were excluded because the reviewers could not
generate a 2 X 2 contingency table [37-39], one was
excluded because it detected TREM-1 mRNA not
sTREM-1 [40], two were excluded because it detected
sTREM-1 in bronchoalveolar lavage fluid [41] or urine
[12], and one was excluded because it targeted on
neonates [42]. Three studies were included in the updated
search (15 October 2012) [23-25]. Totally, 11 studies were
included for the pooled analysis [9,16-25] (Figure 1). The
Cohen Κ statistic for agreement on study inclusion was
0.92.
A total of 1,795 patients were included, comprising 933
patients from ICU in eight studies [9,18-21,23-25], and
Figure 1 Study identification, inclusion, and exclusion for meta-analysis. Flow-chart of study selection.
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862 patients from emergency departments in three studies
[16,17,22]. Mean age varied from 31 to 69 years and the
proportion of male ranged from 48% to 77%. The selected
studies included a wide case mix, including trauma, medi-
cal and surgical illnesses. Among 1,795 patients included,
SIRS criteria were fulfilled in 1,723 patients, including
1,076 septic patients and 647 non- infectious SIRS
patients. Four studies recruited a group of well-matched
(age and sex) patients without SIRS (10 patients in Soud
et al.’s [16], 37 patients in Barati et al.’s [19], 10 patients in
Giamarellos et al.’s [21], and 15 patients in Rivera et al.’s
[20]) as control, and two studies [16,21] included the con-
trol patients as well as non- infectious SIRS patients in the
non-septic group in a 2 X 2 contingency table when ana-
lyzing the diagnostic performance (that is, sensitivity and
specificity) of sTREM-1 for sepsis. The prevalence of sep-
sis across studies ranged from 27% to 73%. To measure
plasma sTREM-1 level, enzyme-linked immunosorbent
assay (ELISA) was used in 10 studies, and Luminex multi-
plex assay in the 1 remaining study [22]. Among the
included studies, the optimal cut-off point was retrospec-
tively determined based on the receiver operating charac-
teristic (ROC) curve and varied greatly, from 40 pg/ml to
755 pg/ml (ELISA method). Details of the included studies
were shown in Table 1.
Quality assessment
Studies were grouped according to Sackett and Haynes’
classification for diagnostic studies: two were phase 2 stu-
dies (group 1) [16,21] and nine phase 3 studies (group 2)
[9,17-20,22-25]. All the included studies fulfilled the
requirements of acceptable reference standard, partial
verification bias avoided, differential verification bias
avoided, incorporation bias avoided, detailed description
of index test, blinding of investigators to reference, unin-
terpretable results reported and withdrawals explained.
Nine studies [9,17-20,22-25] recruited a representative
spectrum of patients and 10 studies [9,16-24] clearly
described the inclusion criteria. Disease progression bias
was avoided in five studies [9,17,19,24,25]. Eight studies
[9,17-20,22,24,25] fulfilled the requirement of blinding of
investigators to index test. All except one [19] described
in detail the reference standard and clinical data. The
results of the methodological assessment for the included
studies were summarized in Figure 2.
Quantitative data synthesis
The pooled sensitivity and specificity of all studies com-
bined was 79% (95% confidence interval (CI), 65 to 89)
and 80% (95% CI, 69 to 88), respectively (Figure 3). The
pooled positive likelihood ratio (PLR) was 4.0 (95% CI,
2.4 to 6.9) and the pooled negative likelihood ratio (NLR)
was 0.26 (95% CI, 0.14 to 0.48). The area under the ROC
curve was 0.87 (95% CI, 0.84 to 0.89) and the DOR was
16 (95% CI, 5 to 46), indicating a moderate diagnostic
accuracy (Figure 4). The post-test probabilities based on
various pre-test probabilities were illustrated using a
Fagan nomogram (Figure 5).
Among the included studies, eight were conducted in
the ICU and three in the emergency department. The
pooled sensitivity and specificity was 78% (95% CI, 64 to
93) and 84% (95% CI, 76 to 93) in ICU patients, and 83%
(95% CI, 63 to 100) and 68% (95% CI, 47 to 88) in patients
from the emergency department. Nine studies
[9,17-20,22-25] classified as phase 3 studies examined the
diagnostic performance of plasma sTREM-1 for sepsis
among SIRS patients suspected of infection, and the
pooled sensitivity and specificity was 79% (95% CI, 66 to
92) and 76% (95% CI, 66 to 87), respectively. Given that
Gamez et al.’s study [17] accounted for 35% (631/1,795) of
the total sample size, sensitivity analysis without this study
was conducted and the pooled sensitivity and specificity of
the remaining 10 studies was 81% (95% CI, 70 to 92) and
82% (95% CI, 73 to 91).
Investigation of heterogeneity
The between study variability (that is, heterogeneity)
beyond what could be expected by sampling error was
high both for sensitivity (with an I2 of 95.0%) and for
specificity (with an I2 of 92.7%). The bivariate model
analysis revealed that the heterogeneity was only partly
(15%) explained by the threshold effect where variations
in sensitivity and specificity were related to differences
in the cut-off points of sTREM-1 in the included
studies.
The source of heterogeneity was explored by univariate
meta-regression analysis. Assay method, clinical setting,
quality assessment, patient sample size and sepsis preva-
lence were used as covariates. By making each covariate
associate with logit(sensitivity) or logit(specificity), meta-
regression analysis showed that sepsis prevalence signifi-
cantly accounted for the heterogeneity for sensitivity, and
assay method and clinical setting significantly accounted
for the heterogeneity for specificity (Figure 6). When
exploring the source of heterogeneity jointly by making
each covariate associate with logit(sensitivity) and logit
(specificity), meta-regression analysis showed that patient
sample size and assay method were the main sources of
heterogeneity. Subgroup analysis by patient sample size
showed that in the five studies [9,16,20,21,24] with small
sample size, the pooled sensitivity and specificity was
89% (95% CI, 80 to 98) and 91% (95% CI, 84 to 97) respec-
tively, and in the other six studies [17-19,22,23,25] with
large sample size, the pooled sensitivity and specificity was
68% (95% CI, 52 to 84) and 69% (95% CI, 58 to 81),
respectively. Subgroup analysis by sTREM-1 assay method
showed that Kofoed et al.’s study [22] using the Luminex
multiplex assay had 83% sensitivity (95% CI, 50 to 100)
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Table 1 Summary of included studies
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surgical ICUs









725 70/60 0.65 55
Gamez 2011 [17] Colombia ED 631 patients older than
18 years with any of the
items: 1) suspected
infection, 2) fever, 3)
delirium, or 4) acute
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unexplained origin within
24 hours of ED
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Group 1 and group 2 studies represented phase 2 and phase 3 studies according to Sackett and Haynes’ classification for diagnostic studies, respectively. AUC, area under the receiver operating characteristic curve;













Figure 2 Proportion of Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool criteria fulfilled for included studies.
Proportion of all 14 Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool criteria that were fulfilled for eleven studies included in
the meta-analysis.
Figure 3 Forrest plot of the sensitivity and specificity of sTREM-1 for the diagnosis of sepsis. Forrest plot of the sensitivity and specificity
of each individual study, pooled sensitivity and specificity, and I2 statistic for heterogeneity.
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and 40% specificity (95% CI, 6 to 74) and the other 10 stu-
dies using the ELISA had 79% sensitivity (95% CI, 67 to
92) and 83% pooled specificity (95% CI, 76 to 90).
Evaluation of publication bias
Deeks’ funnel plot asymmetry test suggested potential
publication bias (P = 0.02) (Figure 7).
Discussion
Early identification of infection is of vital importance to
the clinical course and outcome of septic patients. An
ideal marker of sepsis should be present early in the
course of the disease, measurable rapidly and easily, of
prognostic significance, sensitive enough to detect infec-
tion in patients with minimal host response, and specific
enough to discriminate infection from other non-infec-
tious SIRS [43].
Biological markers such as procalcitonin and CRP
have been used in the diagnosis of bacterial infections
[44,45]. However, since they are “indirect” markers of
infection, their sensitivity and specificity are not 100%
and vary in different patient groups and indications.
TREM-1 was a recently identified molecule involved in
inflammatory response. Human tissues infected with
bacteria were infiltrated with neutrophils and monocytes
that expressed high levels of TREM-1 [8,46]. TREM-1
amplifies infection-induced inflammatory response sig-
nals primarily through the mediation of adapter protein
DAP12 on the cell surface [47]. sTREM-1, as the soluble
form of TREM-1, released by activated phagocytes, may
be a more “direct” marker of infection. In the present
study, pooled analysis showed that plasma sTREM-1
seemed to have a moderate (0.7 ≤AUC <0.9) diagnostic
accuracy for sepsis since the area under the SROC curve
was 0.87. The pooled sensitivity of plasma sTREM-1 for
the diagnosis of sepsis was 79% and the specificity was
80%. With a hypothetical pretest probability of 62% and
a PLR of 4.0, detecting plasma sTREM-1 for sepsis diag-
nosis would raise the post-test probability to 87%. With
a NLR of 0.26, detecting plasma sTREM-1 reduced the
post-test probability to 30% (Figure 5), showing that
application of plasma sTREM-1 test to sepsis diagnosis
had a moderate value. Recently, several studies reported
that plasma sTREM-1 level could be elevated in non-
infectious disease, such as acute pancreatitis, and non-
infectious inflammation following traumatic lung contu-
sion [48-50]. We inferred that in the non-infectious
SIRS patients, sTREM-1 level was elevated, which might
partly account for its moderate but not high accuracy in
distinguishing septic patients from non-infectious SIRS
patients. To date, none of the proposed biomarkers as a
single test had sufficient (more than 90%) sensitivity and
specificity to discriminate sepsis from SIRS in critically
ill adult patients. A combination of several markers
appears to be a useful approach to improving accuracy
in diagnosing sepsis, which was proved by a recent
paper from Gibot et al. [25]. In their study, although
sTREM-1, PCT and polymorphonuclear CD64 index
were all found to be independent predictors of sepsis, a
combination of them was shown to have a far better
diagnostic performance for sepsis with the area under
the ROC curve to be 97% (95% CI, 95 to 99).
As a single indicator of diagnostic test performance,
DOR is independent of disease prevalence. The DOR of
the included studies ranged from 2.17 to 623.33, and the
pooled DOR was 16. The disparity noticed in the
included studies may result from several reasons. First,
patient sample size varied in the included studies. It was
suggested that small studies tend to overestimate the
effect size [51] and studies based on small sample sizes
may have allowed for a type II error. In the present study,
meta-regression analysis showed that patient sample size
significantly accounted for the heterogeneity. The pooled
DOR of the five studies [9,16,20,21,24] with small sample
size was 90 (95% CI, 20 to 399), higher than that of the
other six studies [17-19,22,23,25] with large sample size
(pooled DOR 5, 95% CI, 3 to 9). Therefore, caution
should be taken when interpreting the results. Another
possible reason was different disease spectrum included.
The pooled DOR of the three studies [16,20,21] which
enrolled trauma or injured patients was 104 (95% CI, 9 to
1,206), higher than that of the remaining studies which
enrolled other kinds of patient spectrum (pooled DOR 8,
95% CI, 3 to 19).
Figure 4 Summary receiver operating characteristic graph of
included studies. Summary receiver operating characteristic graph
with 95% confidence region and 95% prediction region for sTREM-1.
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Two prior meta-analyses concluded that sTREM-1
represented a useful biological marker of bacterial
infection [14] or bacterial pleural effusions [15]. The
meta-analysis by Jing et al. [14] included studies across
a wide range of disease spectrum, and assessed
sTREM-1 level from different sample origins, including
non-directed bronchial lavage fluids, pleural fluid,
plasma, bronchoalveolar lavage fluid, cerebrospinal
fluid and urine. The other meta-analysis by Summah et
al. [15] assessed the diagnostic accuracy of sTREM-1
in the pleural fluid for bacterial pleural effusions. Being
different from them, the present meta-analysis assessed
the diagnostic accuracy of sTREM-1 for sepsis and
focused only on the plasma level of sTREM-1.
Figure 5 Fagan’s nomogram for calculation of post-test probabilities. Fagan’s nomogram for sTREM-1 illustrating post-test probability with
a fixed pre-test probability of 62% for sepsis.
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Although detecting the samples from suspected sites of
infection might result in higher diagnostic accuracy
than detecting the plasma sample, it is faster, easier
and simpler to collect plasma samples.
The present meta-analysis had several limitations. First,
although extensive literature search was conducted, the
number of included studies was small. Second, in the
patients who were clinically diagnosed as having sepsis
Figure 6 Univariable meta-regression and subgroup analysis.
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without microbiological evidence, some degree of misclas-
sification bias may have existed. Third, several studies
reported sTREM-1 could reflect the severity of sepsis and
predict prognosis, we didn’t address this issue. Finally, we
could not determine the ideal cut-off point for plasma
sTREM-1 test because we did not have the raw data to
map out the ROC curve. To determine whether there is a
single threshold or a few important thresholds, further stu-
dies with a larger number of patients are needed.
Conclusions
In summary, plasma sTREM-1 had a moderate diagnos-
tic performance in differentiating sepsis from SIRS in
adult patients. Accordingly, plasma sTREM-1 as a single
marker was not sufficient for sepsis diagnosis in sys-
temic inflammatory patients.
Key messages
• The present study showed that the pooled sensitiv-
ity and specificity of plasma sTREM-1 for sepsis
diagnosis was 79% and 80%, respectively. The area
under the SROC curve was 0.87.
• Plasma sTREM-1 had a moderate diagnostic perfor-
mance in differentiating sepsis from SIRS in adult
patients. Accordingly, as a single marker it was not
sufficient for sepsis diagnosis in systemic inflamma-
tory patients.
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